Rainbow Children's Medicare Limited reported a consolidated net profit after tax of ₹625.40 million for the quarter ended June 30, 2026, marking a 16.2% increase from ₹538.05 million in the corresponding period of FY25. The healthcare provider’s consolidated revenue from operations surged 33.2% year-on-year to ₹4,699.85 million, reflecting robust demand across its hospital network and successful integration of recent acquisitions. This top-line expansion significantly outpaced the growth in professional fees to doctors, which rose to ₹1,238.19 million from ₹917.58 million, indicating improved operational leverage and margin stability despite higher specialist engagement costs.

The Board of Directors approved the unaudited standalone and consolidated financial results at its meeting held on July 30, 2026. The results were subject to a limited review by S.R. Batliboi & Associates LLP, the company’s statutory auditors, in compliance with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The financial statements were prepared in accordance with Ind AS 34.

Financial Performance Highlights

Standalone results showed a more modest growth trajectory, with net profit after tax rising 1.9% to ₹527.06 million from ₹517.20 million in Q1FY25. Standalone revenue from operations increased 22.6% to ₹4,105.47 million. The divergence between standalone and consolidated metrics underscores the contribution of subsidiaries and associates to the group’s overall performance.

Consolidated total income reached ₹4,826.95 million, including other income of ₹127.10 million. Total expenses amounted to ₹3,987.42 million. Employee benefits expense rose to ₹668.50 million, while finance costs increased to ₹212.05 million. The effective tax rate remained stable, with total tax expense recorded at ₹214.13 million.

Strategic Developments and Governance

In a move to strengthen its legal framework, the Board elevated Anshuman Jaiswal from Group Head – Legal to Chief Legal Officer. Effective July 30, 2026, Jaiswal has been designated as Senior Management Personnel (SMP) in accordance with SEBI Listing Regulations. He brings over two decades of experience, including tenures at Amarchand Mangaldas and Greenko Group.

Subsequent to the quarter end, Rainbow Children's Medicare executed definitive transaction documents for a new children and women’s hospital at Malad, Mumbai, through its subsidiary Rainbow Women & Children’s Hospital Private Limited. The transaction is expected to complete in the quarter ended September 30, 2026. Additionally, the company signed a Partnership Interest and Contribution Transfer Agreement to acquire a 64% stake in Super Prime Medical Care LLP for ₹198 million, targeting a running children’s hospital in Nellore, Andhra Pradesh.

What the Numbers Show

The significant gap between standalone revenue growth (22.6%) and consolidated revenue growth (33.2%) highlights the accelerating impact of recent acquisitions on the group’s top line. While professional fees—the largest expense component—grew faster than revenue, suggesting a shift toward higher-complexity care or increased specialist reliance, the overall net profit margin expanded. This indicates that other cost centers, such as material costs and administrative expenses, were managed efficiently, allowing the company to convert higher revenue into disproportionate profit growth.

Rainbow Children's Medicare Limited reported a 33.2% year-on-year rise in consolidated revenue from operations to ₹4,699.85 million for the quarter ended June 30, 2026 (Q1FY27), driven by broad-based growth across its hospital network. Net profit after tax increased 16.2% to ₹625.40 million from ₹538.05 million in the prior year period, reflecting robust patient demand and operational expansion. The strong top-line performance was supported by significant increases in inpatient discharges and outpatient consultations, underscoring the company’s ability to scale services effectively.

The unaudited standalone and consolidated financial results were reviewed by statutory auditors S.R. Batliboi & Associates LLP and approved by the Board of Directors on July 30, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In a related personnel update, the Board approved the elevation of Anshuman Jaiswal from Group Head – Legal to Chief Legal Officer, designating him as Senior Management Personnel with immediate effect.

Financial Performance

Consolidated EBITDA stood at ₹1,346 million, up 29.9% from ₹1,036 million in Q1FY26. However, EBITDA margins contracted slightly to 28.6% from 29.4% in the year-ago period, primarily due to higher professional fees paid to doctors as patient volumes expanded. Profit before tax was ₹839.53 million, compared to ₹713.74 million in Q1FY26. PAT margins remained stable at 13.3%, down 194 basis points from 15.2% in Q1FY26.

The following table summarises key consolidated financial metrics for the quarter:

Standalone revenue from operations increased to ₹4,105.47 million. Standalone profit before tax was ₹705.41 million, compared to ₹688.20 million in the prior year period. Basic earnings per share on a standalone basis rose to ₹5.20 from ₹5.09 in the prior year period.

Operational Highlights

Operational momentum remained healthy with significant growth in key patient volume indicators. Inpatient discharges reached 26,886, up 28% from 20,992 in Q1FY26. Outpatient consultations grew 25% to 410,590, while deliveries increased 23% to 4,910. Occupancy rates improved by 103 basis points to 41.24%, supported by an increase in operational beds to 1,862 from 1,523 in the prior year period.

Strategic Developments

Subsequent to the quarter end, the company executed definitive transaction documents for a new children and women's hospital at Malad, Mumbai, through its wholly owned subsidiary Rainbow Women & Children's Hospital Private Limited. This 100-bed brownfield facility is expected to commence operations in Q1 FY28, marking Rainbow's entry into Western India. Additionally, Rainbow Children’s Medicare Limited signed a Partnership Interest and Contribution Transfer Agreement to acquire a 64% stake in Super Prime Medical Care LLP for an aggregate consideration of ₹198 million. This acquisition targets a running children's hospital in Nellore, Andhra Pradesh, with completion expected in the quarter ended September 30, 2026. The company also acquired a 50-bed brand new hospital in Guntur to strengthen its Andhra Pradesh footprint.

What the Numbers Show

The slight contraction in EBITDA margin — from 29.4% to 28.6% — alongside robust revenue growth underscores margin pressure from higher professional fees to doctors, which grew significantly year-on-year. While patient volumes are expanding rapidly, the cost structure is scaling proportionally, requiring careful management of doctor compensation relative to service pricing to sustain profitability gains. The company continues to expand its footprint with new acquisitions and hospital openings, aiming to replicate its hub-and-spoke model across new geographies. With cash and investments totaling ₹6,129 million as of June 30, 2026, the company is well-positioned to fund its ongoing capital expenditure and merger plans using internal resources.